Literature DB >> 2021717

SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group.

.   

Abstract

OBJECTIVE: To see whether early elective angiography with a view to coronary angioplasty or bypass grafting of a stenosed infarct related vessel would improve outcome in acute myocardial infarction treated by thrombolysis with anistreplase.
DESIGN: Randomised study of two treatment strategies with analysis of results over 12 months.
SETTING: 21 district hospitals and regional cardiac centres in Britain and Ireland.
SUBJECTS: 800 of 993 patients presenting with clinical and electrocardiographic features of acute myocardial infarction up to three hours after the onset of major symptoms. TREATMENT STRATEGIES: Intravenous anistreplase 30 units followed by a standard regimen of heparin, warfarin, and timolol and (in patients so randomised) early angiography plus appropriate intervention. MAIN OUTCOME MEASURE: Death or reinfarction within 12 months.
RESULTS: 397 patients were randomised to receive early angiography plus appropriate intervention (coronary angioplasty in 169 cases, coronary grafting in 59) and 403 patients to receive conservative care (of these, 12 had angioplasty and seven bypass grafting during the initial admission). By 12 months mortality (5.8% (23 patients) in the intervention group v 5.0% (20) in the conservative care group; p = 0.6) and rates of reinfarction (15.1% (60 patients) v 12.9% (52); p = 0.4) were similar in the two groups. No significant differences in rates of angina or rest pain were found at 12 months. Left ventricular ejection fraction at three and 12 months was the same in both groups. Median hospital stay was longer in the intervention group (11 days v 10 days; p less than 0.0001).
CONCLUSION: For most patients given thrombolytic treatment for acute myocardial infarction a strategy of angiography and intervention is appropriate only when required for clinical indications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021717      PMCID: PMC1669414          DOI: 10.1136/bmj.302.6776.555

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  11 in total

1.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

2.  A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion.

Authors:  E J Topol; K Burek; W W O'Neill; D G Kewman; N H Kander; M J Shea; M A Schork; J Kirscht; J E Juni; B Pitt
Journal:  N Engl J Med       Date:  1988-04-28       Impact factor: 91.245

3.  Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands.

Authors:  M L Simoons; P W Serruys; M vd Brand; F Bär; C de Zwaan; J Res; F W Verheugt; X H Krauss; W J Remme; F Vermeer
Journal:  Lancet       Date:  1985-09-14       Impact factor: 79.321

4.  Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions.

Authors:  D G Harrison; D W Ferguson; S M Collins; D J Skorton; E E Ericksen; J M Kioschos; M L Marcus; C W White
Journal:  Circulation       Date:  1984-05       Impact factor: 29.690

5.  Percutaneous transluminal coronary angioplasty after intracoronary streptokinase in evolving acute myocardial infarction.

Authors:  S E Papapietro; W A MacLean; A W Stanley; R G Hess; N Corley; J G Arciniegas; T B Cooper
Journal:  Am J Cardiol       Date:  1985-01-01       Impact factor: 2.778

6.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.

Authors:  F Van de Werf; A E Arnold
Journal:  BMJ       Date:  1988-11-26

7.  Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.

Authors:  M L Simoons; A E Arnold; A Betriu; D P de Bono; J Col; F C Dougherty; R von Essen; H Lambertz; J Lubsen; B Meier
Journal:  Lancet       Date:  1988-01-30       Impact factor: 79.321

8.  Coronary angioplasty in unstable angina and stable angina: a comparison of success and complications.

Authors:  R A Perry; A Seth; A Hunt; M F Shiu
Journal:  Br Heart J       Date:  1988-11

9.  Percutaneous transluminal coronary angioplasty after thrombolytic therapy: a prospective controlled randomized trial.

Authors:  R Erbel; T Pop; K J Henrichs; K von Olshausen; C J Schuster; H J Rupprecht; C Steuernagel; J Meyer
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

10.  Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction.

Authors:  C Düber; A Jungbluth; H J Rumpelt; R Erbel; J Meyer; W Thoenes
Journal:  Am J Cardiol       Date:  1986-10-01       Impact factor: 2.778

View more
  27 in total

1.  Succesful Identification and Management of High-Risk Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Treating myocardial infarction in the post-GUSTO era. A European perspective.

Authors:  M J de Boer; F Zijlstra
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

Review 3.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

4.  Invasive Strategies to Achieve Infarct-Related Artery Patency.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

5.  Infarct zone viability influences ventricular remodelling after late recanalisation of an occluded infarct related artery.

Authors:  N G Bellenger; Z Yousef; K Rajappan; M S Marber; D J Pennell
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

6.  Risk stratification after acute myocardial infarction: is it time to reassess? Implications from the INSPIRE trial.

Authors:  John J Mahmarian; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

7.  Early prognosis after thrombolysis: value of exercise radionuclide ventriculography performed on anti-ischaemic medication.

Authors:  R Lim; L Dyke; D S Dymond
Journal:  Int J Card Imaging       Date:  1991

8.  Contrast echocardiography accurately predicts myocardial perfusion before angiography during acute myocardial infarction.

Authors:  Gregory B Schnell; Albert J Kryski; Luana Mann; Todd J Anderson; Israel Belenkie
Journal:  Can J Cardiol       Date:  2007-11       Impact factor: 5.223

Review 9.  [Thrombolysis in ST-elevation myocardial infarction. Current role in the light of recent studies].

Authors:  H-R Arntz; U Zeymer; P Schwimmbeck
Journal:  Anaesthesist       Date:  2004-05       Impact factor: 1.041

10.  Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial: A randomized, prospective multicenter trial evaluating the role of adenosine Tc-99m sestamibi SPECT for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction.

Authors:  John J Mahmarian; Leslee J Shaw; Gerald H Olszewski; Bradley K Pounds; Maria E Frias; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.